摘要
目的 探讨血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班治疗老年不稳定型心绞痛的有效性和安全性.方法 将＞60岁＜80岁确诊为不稳定型心绞痛（高危组）的138例患者随机分为2组,对照组66例给予阿司匹林、氯吡格雷、低分子肝素、硝酸酯类及其他常规治疗,试验组72例在以上治疗基础上加用替罗非班,48 h持续静脉泵入.观察两组心绞痛症状缓解情况和心电图ST段变化,记录用药后48 h、1周、1个月心脏不良事件包括顽固性心绞痛、心肌梗死、心源性猝死及出血等不良反应发生.结果 与对照组相比,试验组心绞痛缓解有效率高,心电图压低ST明显改善（P＜0.05）,心脏不良事件发生率降低.两组均无严重不良反应,轻微出血反应试验组略高于对照组,但无统计学意义.结论 在阿司匹林、氯吡格雷、低分子肝素基础上加用替罗非班治疗老年不稳定型心绞痛安全、有效.
Objective To study the efficacy and safety of the platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist tirofiban used in elderly patients with unstable angina. Methods 138 patients diagnosed with unstable angina （risk group） aged between 60 and 80 were selected and divided into two groups randomly. The 66 patients in the control group were given aspirin, clopidogrel, low molecular weight heparin, sodium nitrate and the other conventional treatments,while the other 72 patients in treatment group were given tirofiban in addition. Observing the ST segment changes of ECG, adverse cardiac events（including refractory angina, myocardial infarction occurs, sudden cardiac death and bleeding and other adverse reactions）48 hours, 1 week, 1 month after administration. Results Compared with the control group, there was a higher rate in symptom relieving, segment recovery of ECG and adverse cardiac events reducing in the treatment group, the difference was significantly（P〈0.05 ）. Serious adverse events happened in neither group. The rate of minor hemorrhagic reaction in treatment group is slightly higher, but not statistically significant. Conclusion In addition to aspirin, clopidogrel, low molecular weight heparin, tirofiban is safe and effective in elderly patients with unstable angina.
出处
《中国心血管病研究》
CAS
2011年第2期109-111,共3页
Chinese Journal of Cardiovascular Research
